Ionis Pharmaceuticals Looks to Partners to Pay the Bills

Ionis Pharmaceuticals (NASDAQ: IONS) continues to rack up royalties from its spinal muscular atrophy drug Spinraza while the rest of its extensive pipeline basically pays the rest of the biotech's bills.

Metric

Q2 2019

Continue reading

Source Fool.com